1357171-62-0

Name	ML228
Synonyms	ML228 L-228 KC7F2 ML-228 ML 228 CID-46742353 N-([1,1'Biphenyl]-4-ylmethyl)-6-phenyl-3-(2-pyridinyl)-1,2,4-triazin-5-amine N-([1,1-Biphenyl]-4-ylmethyl)-6-phenyl-3-(pyridin-2-yl)-1,2,4-triazin-5-amine 1,2,4-Triazin-5-amine, N-([1,1'-biphenyl]-4-ylmethyl)-6-phenyl-3-(2-pyridinyl)-
CAS	1357171-62-0

Molecular Formula	C27H21N5
Molar Mass	415.49
Density	1.228±0.06 g/cm3(Predicted)
Boling Point	686.0±65.0 °C(Predicted)
Solubility	DMSO: ≥ 35 mg/mL
Appearance	Solid
Color	Pale Yellow to Light Yellow
pKa	2.03±0.63(Predicted)
Storage Condition	-20°C, Inert atmosphere
In vitro study	ML228 (CID-46742353) represents a novel chemotype available to the research community for the study of HIF activation and its therapeutic potential. Not only is the compound substantially different in structure from known HIF activators, ML228 lacks the acidic functional group almost universally present in PHD inhibitors, which may be important for certain disease applications.
In vivo study	ML228 (injection; 1 µg/kg; 7 days) treatments following spinal cord injury (SCI) improves the local hypoxic ischemia environment, reduce SCI secondary injury and promote the recovery of neurological function. Animal Model: SD rat Dosage: 1 µg/kg Administration: injection; 7 days Result: Alleviated SCI of the central nervous system and relieve associated symptoms.

Last Update：2024-01-02 23:10:35

biological activity	ML228 (CID-46742353) is an effective HIF signal pathway activator with EC50 of 1 μM. ML228 activates HIF as well as downstream EGFR.
target	EC50: 1 μM (HIF)
in vitro study	ML228 (CID-46742353) represents a novel chemotype available to the research community for the study of HIF activation and its therapeutic potential. Not only is the compound substantially different in structure from known HIF activators, ML228 lacks the acidic functional group almost universally present in PHD inhibitors, which may be important for certain disease applications.
in vivo study	ML228 (injection; 1 µg/kg; 7 days) treatments following spinal cord injury (SCI) improves the local hypoxic ischemia environment, reduce SCI secondary injury and promote the recovery of neurological function. Animal Model: SD Rat Dosage: 1 µg/kg Administration: injection; 7 days Result: Alleviated SCI of the central nervous system and relieve associated symptoms.
Animal Model:	SD rat
Dosage:	1 µg/kg
Administration:	injection; 7 days
Result:	Alleviated SCI of the central nervous system and relieve associated symptoms.

Last Update：2024-04-09 21:11:58

Product Name: ML228 Visit Supplier Webpage Request for quotation
CAS: 1357171-62-0
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409

Wechat: 18301782025

Product Name: ML228 Visit Supplier Webpage Request for quotation
CAS: 1357171-62-0
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409

Wechat: 18301782025

View History

1357171-62-0

1357171-62-0 Request for Quotation